The Markey Lab was established in October 2021, and focuses on the intersection between the microbiome (and its metabolites) and the outcomes of cancer therapy – especially bone marrow transplantation and other immunotherapies. Our projects take clinical observational findings from studies of the intestinal microbiome (e.g. Markey et al, Blood 2020; Miltiadous et al, Blood 2022) through to mechanistic studies in mouse models. A number of observational studies have been performed supporting associations between the microbiome and transplant and/or immunotherapy outcome, but mechanistic data is currently lacking (e.g. Peled et al, NEJM 2020, Stein Thoeringer et al, Science 2020). Combining hypotheses generated from our clinical data with state-of-the-art immunology techniques in mouse model systems is important for addressing the current knowledge gaps in the field and supporting the design of microbiome-targeted interventions in future.